N. Clay Robbins, the president and CEO of the Lilly Endowment, has been given the additional title of chairman at the Indianapolis-based private charitable foundation.
An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
The global firm with extensive Indiana operations plans to occupy a 40,000-square-foot building to be constructed in the Purdue Research Park Aerospace District, a 980-acre technology park in West Lafayette.
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
Dr. Malaz Boustani leads a 26-person team at Eskenazi Health that is showing the group's approach to health care can improve the mental health of both dementia patients and their care givers.
Patients’ anger over high deductibles and high drug prices is spurring presidential candidates to respond—even as the actual prices of health care services are growing slower than at any time since 1990.
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
The safety-net hospital system in Indianapolis will create the Center for Brain Care Innovation and try to use telemedicine and a digital avatar to reach as many as 150,000 Hoosiers and 10 million patients outside Indiana by 2030.
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Months after a divisive religious freedom law thrust Indiana into an unwanted national spotlight, gay rights supporters and religious conservatives are preparing for another potentially bitter debate.
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
Democrat Joe Hogsett bolstered his cash advantage in the Indianapolis mayoral race against Republican Chuck Brewer, reporting donations of more than $1.56 million in his most recent campaign finance filing.
Eli Lilly and Co. beat Wall Street’s expectations with its third-quarter profit, prompting the drugmaker to raise its full-year forecast by as much as 20 cents per share.
Attracting higher-wage residents is key to future growth as city revenues have stagnated and local governments have become increasingly reliant on income taxes. Republican Chuck Brewer and Democrat Joe Hogsett are proposing ways to bolster Indy neighborhoods.
